Lingzhi Zhou1, Xuejing Lu1, Bensi Zhang2, Yaqi Shi2, Zhuang Li1. 1. Department of Surgery, First Affiliated Hospital of Dali University Dali 671000, Yunnan Province, China. 2. Departament of Human Anatomy, School of Basic Medicine, Dali University Dali 671000, Yunnan Province, China.
Abstract
PURPOSE: The aim of this research was to study the expression of EphA2 to assess its suitability as a new breast cancer target. METHODS: Immunohistochemistry (IHC) was used to detect EphA2 protein expression in pathology tissue samples from 250 cases of breast cancer, and the expression of EphA2 mRNA was detected by in situ hybridization (ISH). Breast cancer cells were isolated and cultured. The expression of EphA2 in the cells was detected by the indirect immunofluorescence assay (IFA), and the expression of EphA2 in breast cancer was analysed. RESULTS: EphA2 protein and mRNA were mainly expressed in tumor cells and vascular endothelial cells. EphA2 protein was expressed in 187 cases, with a positive rate of 74.80%, whereas EphA2 mRNA was expressed in 209 cases, with a positive rate of 83.60%. EphA2 protein and mRNA expression were correlated with lymph node metastasis, clinical stage, and breast cancer histologic grade (P<0.05). In addition, the positive expression rates of EphA2 protein and EphA2 mRNA were correlated (P<0.05). EphA2 was barely expressed in normal breast cells but highly expressed in breast cancer cells. CONCLUSION: EphA2 is highly expressed in breast cancer tissues and has the potential to be a new breast cancer target, providing a preliminary basis for the development of new targeted drugs for breast cancer and the construction of fluorescent-targeted tracers for fluorescence-guided mastoscopic breast-conserving surgery. IJCEP
PURPOSE: The aim of this research was to study the expression of EphA2 to assess its suitability as a new breast cancer target. METHODS: Immunohistochemistry (IHC) was used to detect EphA2 protein expression in pathology tissue samples from 250 cases of breast cancer, and the expression of EphA2 mRNA was detected by in situ hybridization (ISH). Breast cancer cells were isolated and cultured. The expression of EphA2 in the cells was detected by the indirect immunofluorescence assay (IFA), and the expression of EphA2 in breast cancer was analysed. RESULTS:EphA2 protein and mRNA were mainly expressed in tumor cells and vascular endothelial cells. EphA2 protein was expressed in 187 cases, with a positive rate of 74.80%, whereas EphA2 mRNA was expressed in 209 cases, with a positive rate of 83.60%. EphA2 protein and mRNA expression were correlated with lymph node metastasis, clinical stage, and breast cancer histologic grade (P<0.05). In addition, the positive expression rates of EphA2 protein and EphA2 mRNA were correlated (P<0.05). EphA2 was barely expressed in normal breast cells but highly expressed in breast cancer cells. CONCLUSION:EphA2 is highly expressed in breast cancer tissues and has the potential to be a new breast cancer target, providing a preliminary basis for the development of new targeted drugs for breast cancer and the construction of fluorescent-targeted tracers for fluorescence-guided mastoscopic breast-conserving surgery. IJCEP
Authors: Mariangela De Robertis; Luisa Loiacono; Caterina Fusilli; Maria Luana Poeta; Tommaso Mazza; Massimo Sanchez; Luigi Marchionni; Emanuela Signori; Giuseppe Lamorte; Angelo Luigi Vescovi; Jesus Garcia-Foncillas; Vito Michele Fazio Journal: Clin Cancer Res Date: 2016-07-11 Impact factor: 12.531
Authors: Philip D Dunne; Sonali Dasgupta; Patrick G Johnston; Sandra Van Schaeybroeck; Jaine K Blayney; Darragh G McArt; Keara L Redmond; Jessica-Anne Weir; Conor A Bradley; Takehiko Sasazuki; Senji Shirasawa; Tingting Wang; Supriya Srivastava; Chee Wee Ong; Ken Arthur; Manuel Salto-Tellez; Richard H Wilson Journal: Clin Cancer Res Date: 2015-08-17 Impact factor: 12.531
Authors: Jennifer M Brannan; Banibrata Sen; Babita Saigal; Ludmila Prudkin; Carmen Behrens; Luisa Solis; Wenli Dong; B Nebiyou Bekele; Ignacio Wistuba; Faye M Johnson Journal: Cancer Prev Res (Phila) Date: 2009-11-24
Authors: Steven J de Jongh; Jolien J J Tjalma; Marjory Koller; Matthijs D Linssen; Jasper Vonk; Michael Dobosz; Annelies Jorritsma-Smit; Jan H Kleibeuker; Geke A P Hospers; Klaas Havenga; Patrick H J Hemmer; Arend Karrenbeld; Gooitzen M van Dam; Boudewijn van Etten; Wouter B Nagengast Journal: J Nucl Med Date: 2019-10-18 Impact factor: 10.057
Authors: Dana M Brantley-Sieders; Aixiang Jiang; Krishna Sarma; Akosua Badu-Nkansah; Debra L Walter; Yu Shyr; Jin Chen Journal: PLoS One Date: 2011-09-15 Impact factor: 3.240